This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
The plant is meant to support the growing resorbable polymers business of Purac Biomaterials. Purac currently operates a plant for biomedical polymers in The Netherlands. This second facility will be built in the USA. The investment for this new plant will be EUR 15 million. The construction of the facility will start in 2011 and is expected to be completed before the end of the year.
Arno van de Ven, Purac Vice President Chemicals & Pharma comments: “This represents an important step in the biomedical polymer business and shows Purac's continued commitment to this market. It provides us with the capability to support the growth of our existing and new business partners.”
Besides an increase in the production capacity, the new facility will bring Purac Biomaterials more flexibility and a more balanced presence in its global markets.
Menno Lammers, Director of Purac Biomaterials comments: “As an experienced supplier to pharmaceutical and medical device companies, we understand the importance of guaranteed supply continuity. Over the last years, the importance of risk management has increased and with this facility we will be in the unique position to provide our customers with dual sourcing”.
The Purac Biomaterials business comprises Lactide based polymers such as Poly Lactic Acid (PLA) and Lactide/Glycolide Copolymers (PGLA). The technology as developed for Purac's biomedical polymers also formed the basis for Purac's activities in L- and D-Lactides for bioplastics such as Poly Lactic Acid (PLA).
Arno van de Ven, Purac Vice President Chemicals & Pharma comments: “This represents an important step in the biomedical polymer business and shows Purac's continued commitment to this market. It provides us with the capability to support the growth of our existing and new business partners.”
Besides an increase in the production capacity, the new facility will bring Purac Biomaterials more flexibility and a more balanced presence in its global markets.
Menno Lammers, Director of Purac Biomaterials comments: “As an experienced supplier to pharmaceutical and medical device companies, we understand the importance of guaranteed supply continuity. Over the last years, the importance of risk management has increased and with this facility we will be in the unique position to provide our customers with dual sourcing”.
The Purac Biomaterials business comprises Lactide based polymers such as Poly Lactic Acid (PLA) and Lactide/Glycolide Copolymers (PGLA). The technology as developed for Purac's biomedical polymers also formed the basis for Purac's activities in L- and D-Lactides for bioplastics such as Poly Lactic Acid (PLA).
Companies in this press-release
